BioAge Labs, Inc. (BIOA)

BioAge Labs Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-80.61	-71.11	-63.85	-39.72
Depreciation & Amortization	0.21	0.17	0.16	0.13
Stock-Based Compensation	11.69	6.98	3.02	2.54
Other Adjustments	-1.1	1.27	16.6	0.08
Change in Receivables	-0.77	-	-	-
Changes in Accounts Payable	0.79	0.01	-0.39	0.99
Changes in Accrued Expenses	-3.41	4.63	3.73	-0.52
Changes in Unearned Revenue	-6.75	9.19	3.31	-
Changes in Other Operating Activities	-1.69	-2.65	0.06	0.32
Operating Cash Flow	-81.63	-51.52	-37.36	-36.18
Capital Expenditures	-0.72	-0.37	-0.17	-0.1
Purchases of Investments	-154.75	-	-0.1	-
Proceeds from Sale of Investments	60.25	-	-	-
Investing Cash Flow	-95.22	-0.37	-0.27	-0.1
Long-Term Debt Issued	-	-	36	2.5
Long-Term Debt Repaid	-6	-6	-1	-
Net Long-Term Debt Issued (Repaid)	-6	-6	35	2.5
Issuance of Common Stock	17.87	222.25	0	0.04
Net Common Stock Issued (Repurchased)	17.87	222.25	0	0.04
Issuance of Preferred Stock	-	170	-	-
Net Preferred Stock Issued (Repurchased)	-	170	-	-
Other Financing Activities	-0.4	-5.05	-0.06	-0.05
Financing Cash Flow	11.47	381.2	34.94	2.5
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.09	0.08	-	0.25
Net Cash Flow	-165.46	329.39	-2.69	-33.54
Free Cash Flow	-82.35	-51.89	-37.53	-36.28
FCF Margin	-915.46%	-	-	-
Free Cash Flow Per Share	-2.29	-4.84	-22.43	-21.70
Levered Free Cash Flow	-98.17	-66.13	-22.15	-36.4
Unlevered Free Cash Flow	-104.35	-67.22	-41.69	-39.15

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q